PTSM: Pharmaceutical Technology Sourcing and Management, Mar 2, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Mar 2, 2011
Biologics
The US Biosimilar Regulatory Scheme and Comparison with the European Experience: Where Do Where Go From Here?
By David Rosen , Larry Lian
The authors outline the key decision points FDA must consider in putting forth a US regulatory pathway for biosimilars.
Contract Manufacturing
A Roundup of Informex
By Patricia Van Arnum
Contract manufacturers and fine-chemical suppliers announce capacity expansions and service enhancements of Informex.
Outsourcing
Changes Underway for Biopharmaceutical Outsourcing
By Eric Langer
More crucial biomanufacturing operations are expected to be outsourced.
CSR and Sustainability Forum
Drug Development for Government, Nonprofit, and Developing-World Markets
By Chan Harjivan , George Dougherty
This article is Part I of a three-part series on biopharmaceutical issues in public health, government, and developing-world markets. Part 1 focuses on drug-development. Part II, which examines manufacturing, appeared in the April 2011 of Sourcing and Management. Part III, which analyzes distribution and administration,appeared in the May 2011 issue.
Bristol-Myers Squibb Moves Forward with HIV/AIDS Project in Africa
By Patricia Van Arnum
Bristol-Myers Squibb opens a new pediatric HIV/AIDS clinic in Tanzania.
CSR and Sustainability Forum
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here